Randomized multicenter clinical evaluation of Xiaoer Kechuanling oral liquid (concentrated type) in the intervention of respiratory syncytial virus pneumonia in children (syndrome of heat pathogen blocking lung)

Phase 1

• Conditions: Respiratory syncytial virus pneumonia in children

• Registration Number: ITMCTR2200006404
• Lead Sponsor: The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.Children who meet the diagnosis of respiratory syncytial virus pneumonia;
2.Children who meet the TCM diagnosed pneumonia with dyspneic cough with syndrome of heat pathogen blocking lung;
3.Aged from 1 to 5;
4.The course of RSV pneumonia is within 48 hours;
5.The legal guardian and the child who can understand and sign his/her name have understood and signed the informed consent.

Exclusion Criteria

1. Drugs taken within 24 hours before onset that may affect the efficacy evaluation of the test (such as antipyretic and analgesic drugs, antibacterial drugs, H1 receptor blockers, vasoconstrictor and Traditional Chinese medicines with the same efficacy as the test drugs, etc.);
2. Severe pneumonia in children (according to the criteria for classification of severity according to 2013 Guidelines for The Management of Community-acquired Pneumonia in Children);
3. Patients with onset of other respiratory diseases except pneumonia;
4. Allergic to the test drug;
5. Patients who have participated in or are participating in clinical trials of other drugs within the last 3 months;
6. According to the doctor's judgment, it is easy to lose visitors.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time window of therapeutic effect for pediatric syncytial virus pneumonia;The total response rate of the disease;

Secondary Outcome Measures

Name	Time	Method
Combined with medication use;TCM syndrome effect;Single symptom curative effect;